Prostate neoplasm
Therapeutic area
Oncology
Rare disease
No
- Definition
- A neoplasm (disease) that involves the prostate gland.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Prostate neoplasm
- Therapeutic area
- Oncology
- prostate neoplasm
- neoplasm of prostate
- neoplasm of prostate gland
- neoplasm of the prostate
- prostate gland neoplasm
- prostate gland neoplasm (disease)
- prostate gland tumor
- prostate gland tumour
- prostate tumor
- prostate tumour
- tumor of prostate
- tumor of prostate gland
- tumor of the prostate
- tumour of prostate
- tumour of prostate gland
- tumour of the prostate
- Severity
- Severe
- Oncology
- Reproductive Health
- MONDO ID
- MONDO:0021259
- Parent condition
- MONDO:0003105
Related records
Broader conditions (11)
- Cancer or benign tumor
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Human disease
- Male reproductive system disorder
- Neoplasm
- Neoplastic disease or syndrome
- Prostate disorder
- Reproductive system disorder
- Reproductive system neoplasm
Narrower conditions (53)
- Acinar prostate adenocarcinoma, foamy gland variant
- Acinar prostate adenocarcinoma, signet ring variant
- Acinar prostate mucinous adenocarcinoma
- Adenosquamous prostate carcinoma
- Benign neoplasm of prostate
- Benign prostate phyllodes tumor
- Castration-resistant prostate carcinoma
- Familial prostate carcinoma
- Fibroma of prostate
- Grade III prostatic intraepithelial neoplasia
- Hormone-resistant prostate carcinoma
- Lymphoepithelioma-like acinar prostate adenocarcinoma
- Malignant prostate phyllodes tumor
- Metastatic prostate carcinoma
- Primary prostate urothelial carcinoma
- Prostate adenocarcinoma
- Prostate adenoid cystic carcinoma
- Prostate angiosarcoma
- Prostate cancer
- Prostate cancer, hereditary
Trials (114)
- 18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer
- 18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer
- 18F-FMAU PET/CT in Diagnosing and Characterizing Prostate Cancer
- A Drug-Drug Interaction Study of Abiraterone Acetate Plus Prednisone With Dextromethorphan and Theophylline in Patients With Metastatic Castration-Resistant Prostate Cancer
- A Pharmacokinetics Study to Assess Abiraterone Acetate Capsule and Tablet Formulations in Patients With Prostate Cancer
- A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer
- A Phase II Trial of CyberKnife Stereotactic Radiosurgery to Prostate Tumors
- A Pilot Study of 5-AZA and ATRA for Prostate Cancer With PSA-only Recurrence After Local Treatment
- A Pilot Study of Vaccination With Epitope-Enhanced TARP Peptide and TARP Peptide-Pulsed Dendritic Cells in the Treatment of Stage D0 Prostate Cancer
- A Prospective Pilot Study for the Evaluation of 18F- Fluciclovine PET/MRI in Radio-recurrent Prostate Cancer (RRPC-PET/MRI Study)
- A Prospective Study Of Free-Hand Transperineal Image Fusion Targeted Biopsies Under Local Anesthesia
- A QT/QTc and Multi-Dose Pharmacokinetic Study of Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
- A Safety Study of Abiraterone Acetate Administered in Combination With Docetaxel in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC)
- A Study of Abiraterone Acetate Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer
- A Study of Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy
- A Study of LY4257496 in Participants With Cancer (OMNIRAY)
- A Study of MDV3100 to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of in Prostate Cancer Patients
- A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer
- A Study to Determine the Maximum Tolerated Dose of ASG-5ME in Subjects With Castration-Resistant Prostate Cancer
Approved drugs (5)
Drugs in development (9)
- 5-methyl-2'-fluoroarauracil F-18 Phase 1
- Abiraterone Phase 3
- Bortezomib Phase 2
- Degarelix Phase 3
- Estetrol Phase 2
- Lutetium LU-177 psma-R2 Phase 1
- Pasritamig Phase 1
- Prednisone Phase 3
- Vipivotide tetraxetan Phase 1
Other linked drugs (13)
- Abiraterone acetate
- Bicalutamide
- Docetaxel
- Dutasteride
- Fluciclovine F18
- Gallium GA 68 gozetotide
- Ifosfamide
- Leuprolide
- Leuprolide acetate
- Padeliporfin
- Radium RA 223 dichloride
- Satraplatin
- Temsirolimus